Recruiting
Phase 1

Triheptanoin

Sponsor:

Jirair Krikor Bedoyan

Code:

NCT06340685

Conditions

Pyruvate Dehydrogenase Complex Deficiency

Eligibility Criteria

Sex: All

Age: 1 - 17

Healthy Volunteers: Not accepted

Interventions

Triheptanoin

Study Details

Brief summary:

This is a medical research study to test a medication in patients with a disease called Pyruvate Dehydrogenase Complex (PDC) Deficiency. The medication is triheptanoin, which is currently FDA approved for the treatment of Long-Chain Fatty Acid Oxidation Disorders. Previous research suggests that triheptanoin may also be effective in the treatment PDC Deficiency. This study will investigate the safety and efficacy (how well it works) of triheptanoin in patients with PDC Deficiency.

Conditions

Pyruvate Dehydrogenase Complex Deficiency

Study ID

NCT06340685

Start date

Jul 11, 2024

Status verified date

Feb, 2026

Completion date

Jun 30, 2029

Anticipated

Primary completion date

Dec 31, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 1 - 17

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Age 1 year to <18 years of age
2. Subjects with PDCD would need to have a metabolic physician following their clinical care needs prior to their enrollment in the study
3. Diagnosis of PDCD by molecular genetic confirmation of PDHA1, PDHB, DLAT, PDHX, or PDP1 mutation
4. Not pregnant or lactating
5. Parental permission and assent of minor and willingness to comply with study procedures
6. Not participating in any interventional treatment clinical trials
7. Not a recipient of gene therapy, organ transplant, or bone-marrow transplantation
8. If currently on any investigational drugs or therapies, must complete a 30-day washout period prior to Intake \& Dosing (Day 1).
9. Negative pregnancy test for all female patients of childbearing age. Individuals of childbearing potential must agree to use a highly effective method of contraception, and males must agree not to father a child or donate sperm. True abstinence for the duration of the study will also be accepted.
10. Subjects are following some form or type of ketogenic diet at the time of the screening visit.

Exclusion Criteria:

1. Diagnosis of medium-chain acyl-CoA dehydrogenase (MCAD)
2. Use of alcohol or drugs of abuse
3. Evidence of liver disease as defined by elevations of AST or ALT >2x ULN in the past 6 months
4. Pregnant, breastfeeding, or lactating females
5. On any investigational product research study (and not completed the required 30-day washout period prior to Intake \& Dosing) or recipient of gene therapy or organ or bone-marrow transplantation

Study Design

Enrollment

6 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Triheptanoin

Open label study

Interventions

Triheptanoin

Open-label design with doses of triheptanoin up to 4.0 gm/kg triheptanoin

Primary outcome measure

  • Number of participants who report side-effects related to gastrointestinal (GI) distress [ Time Frame: 24 months ]
  • Normalization of biochemical markers of disease (lactate) [ Time Frame: 24 months ]
  • Normalization of biochemical markers of disease (pyruvate) [ Time Frame: 24 months ]
  • Normalization of biochemical markers of disease (β-hydroxybutyrate level) [ Time Frame: 24 months ]
  • Normalization of biochemical markers of disease (Alanine/Leucine ratio) [ Time Frame: 24 months ]
  • Normalization of biochemical markers of disease (Alanine/Lysine ratio) [ Time Frame: 24 months ]
  • Normalization of biochemical markers of disease (Alanine/Proline ratio) [ Time Frame: 24 months ]
  • More efficacious seizure control [ Time Frame: 24 months ]
  • More efficacious metabolic control [ Time Frame: 24 months ]
  • More efficacious disease control [ Time Frame: 24 months ]

Central Contacts and Locations

Central contacts

Jirair Bedoyan, MD, PhD

bedoyanjk@upmc.edu

Locations

UPMC Children's Hospital of Pittsburgh

Recruiting

Pittsburgh, Pennsylvania, United States, 15224

Principal Investigator:

Jirair Bedoyan, MD, PhD

More Information

Sponsor

Jirair Krikor Bedoyan

Last update posted

Feb 17, 2026

Last verified

Feb, 2026

Keywords

  • Pyruvate Dehydrogenase Complex Deficiency

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Jirair Krikor Bedoyan on 2026-02-17.